

- d. Pro at position 217 is replaced by any naturally occurring amino acid other than Pro;
- e. Arg at position 218 is replaced by any naturally occurring amino acid other than Arg;
- f. Ala at position 219 is replaced by any naturally occurring amino acid other than Ala;
- g. Gly at position 220 is replaced by any naturally occurring amino acid other than Gly;
- h. Arg at position 221 is replaced by any naturally occurring amino acid other than Arg;
- i. Ala at position 222 is replaced by any naturally occurring amino acid other than Ala.

3. (Amended) A FLINT analog as in Claim [1] 2 comprising an amino acid substitution in the region defined by amino acids 214 through 222 of SEQ ID NO:1, selected from the group consisting of:

- a. Gly at position 214 is replaced by a positively charged amino acid that is not Gly;
- b. Pro at position 215 is replaced by a positively charged amino acid that is not Pro;
- c. Thr at position 216 is replaced by a positively charged amino acid that is not Thr;
- d. Pro at position 217 is replaced by a positively charged amino acid that is not Pro;
- e. Arg at position 218 is replaced by a positively charged amino acid that is not Arg;
- f. Ala at position 219 is replaced by a positively charged amino acid that is not Ala;
- g. Gly at position 220 is replaced by a positively charged amino acid that is not Gly;
- h. Arg at position 221 is replaced by a positively charged amino acid that is not Arg; or

Ala
Cm.t
09956019-000704
T02000

- $$A_{cm} \times 0.00001$$

- Gly at position 214 is replaced by a nonpolar amino acid that is not Gly;
- Pro at position 215 is replaced by a nonpolar amino acid that is not Pro;
- Thr at position 216 is replaced by a nonpolar amino acid that is not Thr;
- Pro at position 217 is replaced by a nonpolar amino acid that is not Pro;
- Arg at position 218 is replaced by a nonpolar amino acid that is not Arg;
- Ala at position 219 is replaced by a nonpolar amino acid that is not Ala;

- g. Gly at position 220 is replaced by a nonpolar amino acid that is not Gly;
- h. Arg at position 221 is replaced by a nonpolar amino acid that is not Arg; or
- i. Ala at position 222 is replaced by a nonpolar amino acid that is not Ala.

A1
Conced

7. (Amended) A FLINT analog [as in Claim 1] resistant to proteolysis at position 218 of SEQ ID NO:1 comprising an amino acid substitution in SEQ ID NO:1, selected from the group consisting of:

- a. Arg at position 218 is replaced by Gln;
- b. Arg at position 218 is replaced by Glu;
- c. Thr at position 216 is replaced by Pro;
- d. Arg at position 218 is replaced by Ala;
- e. Arg at position 218 is replaced by Gly;
- f. Arg at position 218 is replaced by Ser;
- g. Arg at position 218 is replaced by Val
- h. Arg at position 218 is replaced by Tyr;
- i. Arg at position 218 is replaced by Asn; and
- j. Pro at position 217 is replaced by Tyr.

0993019-000701

14. (Amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically-effective amount of a protease resistant FLINT analog of Claim [1-13] 2.

A2

16. (Amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of Claim [1-13] 2 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

A3